Deutsche Märkte schließen in 4 Stunden 21 Minuten

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
38,41-0,84 (-2,14%)
Börsenschluss: 4:00PM EDT
38,83 +0,42 (+1,09%)
Vorbörslich: 06:57AM EDT
Melden Sie sich an, um eine Nachricht zu posten.
  • K
    Kenneth
    CRISPR Therapeutics AG
    $DTIL using proprietary ARCUS gene editing for CD19 posted 75% and 50% ORR and CRR vs CRSP 58% and 38%. $DTIL is at 10% of the market cap and doesn't share patent rights with $EDIT $NTLA $BEAM etc..
  • O
    Offer
    $ALLO conversation
    I am still trying to learn... Who are these market makers and how do they enforce their view in sense of share price. This $ALLO fall reminds me of the $NTLA jump we saw for good data for which I wondering the same thing. There was a huge price change in NTLA from 80 to 160 and in ALLO from ~20 to ~10. I understand that during the trading day the price could move based on demand in the free market but the huge jumps between trading days I am still trying to understand. Why was the NTLA price jumping to 160? Why not 120? Why not 200? ALLO fall, why to 13? Why not to 7? Why not to 16? Who makes these decisions on the new price after an announcement and how do they enforce it on the market for all of us to take it for granted? Adding the $EDIT $BEAM $CRSP community in case they have the answers. Thanks!
  • R
    RV
    $EDIT conversation
    https://kvgo.com/corporate-services/EDIT-101-Clinical-Data-Review

    The link to tomorrow’s presentation ( $EDIT )

    Starts at 10:05 ET
  • R
    RV
    $EDIT conversation
    Anybody selling check this out before you sell:

    Brad Loncar
    @bradloncar
    ·
    2h
    $EDIT data came in about exactly what you’d expect from a few patients at mid dose. Hints that it could work but not enough to give you confidence that it will work. In other words, a borderline non-event that won’t make anyone happy.
    Fyodor Urnov
    @UrnovFyodor
    Replying to
    @bradloncar
    I strongly (and respectfully) disagree.

    1. No immune response (so far)
    2. AAV-Cas9 in eye is safe (to date)
    3. Modest response in mid-dose
    4. Advancing to peds

    = this is substantial for Editas, and the field
    9:52 AM · Sep 29, 2021·Twitter Web App
  • R
    RV
    $NTLA conversation
    Evaluations:
    Evaluations of EDIT vs NTLA:

    CRISPR Investors
    @CrisprInvestors
    ·
    4h
    Not saying $NTLA ‘s valuation at 11B is right or wrong…..
    But if $EDIT gives us pretty convincing data on the 29th and hints at even better data coming December,
    Then, $EDIT deserves to be trading at the same or similar valuation as $NTLA

    Ⓜ Alexander
    @MSandersvn
    ·
    14m
    Replying to
    @CrisprInvestors

    @pharmacreep
    and
    @Mykalt45
    TAM for NTLA-2001 is about 250x more than EDIT-101
    Outside of NTLA not wholly owning the majority of their programs, I think it’s hard to argue EDIT having similar valuation in my opinion
  • S
    Short Legend
    $CRSP conversation
    This board reminds me of all the cheerleaders on the $EDIT board who were celebrating the results from their most recent clinical trial readout l saying they were great. We all know how that turned out with the stock getting cut almost in half since.
  • R
    RV
    $EDIT conversation
    Heather King
    @HK_gene_targets
    Can we all take a min to thank the folks
    @editasmed
    , the physicians, and especially the trial participants for the incredibly informative data set they just provided everyone in #GeneEditing ? 1st data for therapeutic photoreceptor editing in humans $EDIT #CRISPR
    1:37 PM · Sep 29, 2021
  • S
    Short Legend
    $ALLO conversation
    Chromosomal abnormalities were found - sell all CRISPR stocks.

    $EDIT $CRSP $NTLA
  • R
    RV
    $EDIT conversation
    Yep!

    Nat Harooni DNA
    @NatHarooni
    ·
    1h
    Level 1:
    $EDIT-101:

    “I would like to thank all of the patients who have and will participate in this landmark gene editing medicine clinical trial”

    -Language seems to imply trial safe enough to move forward.
    -Recent hiring spree, particularly w/ In Vivo, is Stargardt Tx on the way?
  • C
    Chill
    $EDIT conversation
    Last chance to fetch some $EDIT below 60 USD.
  • S
    Short Legend
    $CRSP conversation
    Even the terrible $EDIT is outperforming this today - must be bad results coming next week. Could be another great short opportunity like we recently had when $EDIT announced poor results.
  • i
    iamaverb
    $BEAM conversation
    September is National Sickle Cell Disease Awareness Month and it seems now would be the perfect month for $EDIT and $BEAM to kick off their Sickle Cell programs, with EDIT beginning their first dosing and BEAM filing their first IND.
  • i
    iamaverb
    $BEAM conversation
    $EDIT is on its 30-day countdown to releasing the long-awaited data on their first in-vivo CRISPR editing clinical trials, and since the 1st of the month 2 days ago, the share price has risen $10 a share or roughly 17%.
    As in life, as in games, you must be present to win, and now is the time for $BEAM to get in the game and file an IND for their first clinical trial.
  • R
    RV
    $BEAM conversation
    CRISPR Investors
    @CrisprInvestors
    ·
    43s
    If you own $EDIT $CRBU $VERV $BEAM $NTLA $GRPH $CRSP …..

    You should spend your time reading……
    @nature White heavy check mark
    @CellCellPress White heavy check mark
    @ScienceMagazine White heavy check mark

    You should spend less time reading……
    @CNBC
    @WallStreetJour1
    @business
    Replying to @CrisprInvestors @Nature and 5 others
  • S
    Short Legend
    $CRSP conversation
    Chancers who missed out on big $NTLA gains have been crushed recently on $EDIT and CRSP. The market is not forgiving when mediocre results are presented.
  • W
    Wenliang
    $EDIT conversation
    Can anyone tell me why Feng Zhang's team's research of Cas13a for RNA edit was licensed to $BEAM instead of $EDIT? I think his team is the science advisory panel of $EDIT, no?
  • S
    Short Legend
    $EDIT conversation
    Adam Feuerstein 💉
    @adamfeuerstein
    ·
    2h
    But y'day, $EDIT made it nearly impossible for reporters to do their job. The co. withheld results from us way past agreed upon timelines. I was forced to interview the CMO w/o any data or info to look at in advance. All-important data slides were not sent until the evening.
  • R
    RV
    $CRBU conversation
    $CRBU doing well today while all others $BEAM, $NTLA, $CRSP and $EDIT are having down days. Every Gene Editing stock has its day.
  • S
    Short Legend
    $EDIT conversation
    The oracle spoke and gave you plenty of warning in good time. Those who didn't take heed the warning are now suffering the consequences. Remember there's still a lot further to drop.

    Short Legend17 days ago
    $EDIT conversation
    "I'm in it for the long haul" - that's what rookie investors tell themselves as they watch profits disappear time and time again.

    You've already seen this go down from $100 to $30 earlier this year and I bet the same rookies will sit on their hands and ride it back down to $20 this time around. Meanwhile, those who know what they're doing make money in both directions and I can assure you the next direction for this stock will be DOWN!